Demographic features of study populations
| Demographic feature . | n . |
|---|---|
| Age (y), median (range) | 54 (23-73) |
| Sex (%) | |
| Male | 18 (62) |
| Female | 11 (38) |
| Race (%) | |
| Black | 8 (29) |
| White | 17 (59) |
| Asian | 3 (10) |
| Other | 1 (3) |
| Ethnicity (%) | |
| Hispanic | 7 (24) |
| Non-Hispanic | 22 (76) |
| Disease type (%) | |
| B-cell lymphomas | 7 (24) |
| Burkitt | 1 (3) |
| DLBCL | 1 (3) |
| Follicular | 5 (17) |
| T-cell lymphomas | 18 (62) |
| ATLL | 6 (21) |
| ALCL ALK(−) | 3 (10) |
| Sezary syndrome | 2 (7) |
| CTCL | 1 (3) |
| CD4+ T cell | 1 (3) |
| Hepatosplenic T cell | 1 (3) |
| Intestinal T cell | 1 (3) |
| NK T cell | 1 (3) |
| PTCL | 1 (3) |
| SPTL-AB | 1 (3) |
| Other | 4 (14) |
| Blastic plasmacytoid dendritic cell neoplasm | 1 (3) |
| Hodgkin lymphoma | 3 (10) |
| Prior therapies, median (range) | 3 (1-16) |
| CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD | 24 (83) |
| Experimental therapies: clinical trials | 11 (38) |
| Gemcitabine based: GEM/GemiFOX/GemOX/GVD | 9 (31) |
| HDAC inhibitors | 9 (31) |
| Alkylator based: Benda/CTX/CVP | 8 (28) |
| Platinum based: RICE/ICE/DHAP/ESHAP | 7 (24) |
| Radiation | 7 (24) |
| Biologics: bexarotene/ublituximab/Rituxan | 7 (24) |
| Autologous stem cell transplant | 6 (21) |
| MTX/SMILE | 5 (17) |
| ABVD/ABV-COPP/MOPP | 4 (14) |
| Brentuximab vedotin | 4 (14) |
| Lenalidomide based | 4 (14) |
| Phototherapy: light/PUVA | 3 (10) |
| Pralatrexate | 2 (7) |
| Allogeneic transplant | 1 (3) |
| Demographic feature . | n . |
|---|---|
| Age (y), median (range) | 54 (23-73) |
| Sex (%) | |
| Male | 18 (62) |
| Female | 11 (38) |
| Race (%) | |
| Black | 8 (29) |
| White | 17 (59) |
| Asian | 3 (10) |
| Other | 1 (3) |
| Ethnicity (%) | |
| Hispanic | 7 (24) |
| Non-Hispanic | 22 (76) |
| Disease type (%) | |
| B-cell lymphomas | 7 (24) |
| Burkitt | 1 (3) |
| DLBCL | 1 (3) |
| Follicular | 5 (17) |
| T-cell lymphomas | 18 (62) |
| ATLL | 6 (21) |
| ALCL ALK(−) | 3 (10) |
| Sezary syndrome | 2 (7) |
| CTCL | 1 (3) |
| CD4+ T cell | 1 (3) |
| Hepatosplenic T cell | 1 (3) |
| Intestinal T cell | 1 (3) |
| NK T cell | 1 (3) |
| PTCL | 1 (3) |
| SPTL-AB | 1 (3) |
| Other | 4 (14) |
| Blastic plasmacytoid dendritic cell neoplasm | 1 (3) |
| Hodgkin lymphoma | 3 (10) |
| Prior therapies, median (range) | 3 (1-16) |
| CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD | 24 (83) |
| Experimental therapies: clinical trials | 11 (38) |
| Gemcitabine based: GEM/GemiFOX/GemOX/GVD | 9 (31) |
| HDAC inhibitors | 9 (31) |
| Alkylator based: Benda/CTX/CVP | 8 (28) |
| Platinum based: RICE/ICE/DHAP/ESHAP | 7 (24) |
| Radiation | 7 (24) |
| Biologics: bexarotene/ublituximab/Rituxan | 7 (24) |
| Autologous stem cell transplant | 6 (21) |
| MTX/SMILE | 5 (17) |
| ABVD/ABV-COPP/MOPP | 4 (14) |
| Brentuximab vedotin | 4 (14) |
| Lenalidomide based | 4 (14) |
| Phototherapy: light/PUVA | 3 (10) |
| Pralatrexate | 2 (7) |
| Allogeneic transplant | 1 (3) |
ABV-COPP, adriamycin, bleomycin, vinblastin, cyclophosphamide, vincristine, procarbazine, prednisone; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CTCL, cutaneous T-cell lymphoma; CTX, cyclophosphamide; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CVP, cyclophosphamide, vincristine, prednisone; DHAP, dexamethasone, high dose cytarabine, cisplatin; DLBCL, diffuse large B-cell lymphoma; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, adriamycin; ESHAP, etoposide, solumedrol, high dose cytarabine, cisplatin; GEM, gemcitabine; GemiFOX, gemcitabine, ifosfamide, oxaliplatin; GemOX, gemcitabine, oxaliplatin; GVD, gemcitabine, vinorelbine, doxil; ICE, ifosfamide, carboplatin, etoposide; MOPP, mustargen, vincristine, procarbazine, prednisone; MTX, methotrexate; NK, natural killer; PUVA, psoralen and UV A; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RICE, rituxan, ifosfamide, carboplatin, etoposide; SPTL-AB, subpanniculitis-like T-cell lymphoma alpha/beta.